RxDoctor Payments Data

Deepak Jaiswal, MD

Internal Medicine · Durant, OKNPI 1386698728

Payments from drug & device makers

$870in general payments, 2019–2025

Across 52 payments — averaging $16.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Gilead$275
  • Pfizer$157
  • Lilly USA, LLC$71
  • Abbott$70
  • Indivior Inc.$53
  • GSK$37
  • plus $208 from 12 others

What the payments were for

  • Food & beverage$85999%
  • Education$121%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Gilead15$275
Pfizer10$157
Lilly USA, LLC5$71
Abbott3$70
Indivior Inc.3$53
GSK3$37
Analog Devices Inc.2$26
Heartflow, Inc.1$21
Exact Sciences1$20
Novo Nordisk1$19
Genentech USA, Inc.1$19
Johnson & Johnson1$17
Medtronic1$16
Pear Therapeutics (US), Inc.1$16
Boehringer Ingelheim1$16
Melinta Therapeutics, LLC1$14
AbbVie1$13
Novartis1$11

How this compares

$870 in reported general payments places this provider in the 65th percentile of 840 internal medicine providers in Oklahoma.

See all internal medicine providers in Oklahoma

Medicare billing

Part B allowed, 2024
$250,617
Medicare patients
251
Services billed
5,848

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl389$59,612
OzempicSemaglutide56$59,350
JanuviaSitagliptin Phosphate44$49,167
EliquisApixaban42$41,701
Trelegy ElliptaFluticasone/Umeclidin/Vilanter31$40,468
MounjaroTirzepatide33$33,772
JardianceEmpagliflozin19$24,659
ZubsolvBuprenorphine Hcl/Naloxone Hcl25$15,497
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen659$15,348
XareltoRivaroxaban22$13,051
SuboxoneBuprenorphine Hcl/Naloxone Hcl11$8,745
Breo ElliptaFluticasone/Vilanterol16$7,967
Arnuity ElliptaFluticasone Furoate13$5,827
Albuterol Sulfate HfaAlbuterol Sulfate128$5,277
SymbicortBudesonide/Formoterol Fumarate14$4,548

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$19$59,35056 claims
GSKTrelegy Ellipta, Breo Ellipta, Arnuity Ellipta$37$54,26160 claims
PfizerEliquis$157$41,70142 claims
Lilly USA, LLCMounjaro$71$33,77233 claims
Boehringer IngelheimJardiance$16$24,65919 claims
Johnson & JohnsonXarelto$17$13,05122 claims
Indivior Inc.Suboxone$53$8,74511 claims
AbbVieSynthroid$13$1,69213 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 840 internal medicine providers in Oklahoma.

Other internal medicine in Durant

See the full list for Oklahoma

Where these figures come from

Is this you, or does something look wrong? →